Media headlines about Biocept (NASDAQ:BIOC) have trended somewhat positive on Thursday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biocept earned a news impact score of 0.04 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.3750566428966 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Global Liquid Biopsy Market Size 2018 – JANSSEN DIAGNOSTICS, BIOCEPT, INC., MYRIAD GENETICS and LLC. (exclusivereportage.com)
- VWR, Part of Avantor, and Biocept Announce the Launch of CEE-Sure Blood Collection Tubes for cfDNA and CTCs (finance.yahoo.com)
- Biocept’s (BIOC) CEO Michael Nall on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Circulating Tumor Cells Market Analysis by 2025: Top Companies Like Sysmex, Ikonisys, Biocept, Fluidigm, Epic Sciences (digitaljournal.com)
- Valuable Sizzling Stock of Monday: Biocept, Inc. (BIOC) (nasdaqexpress.com)
NASDAQ:BIOC traded up $0.01 during trading hours on Thursday, reaching $0.25. 6,260 shares of the company’s stock were exchanged, compared to its average volume of 2,018,790. The stock has a market capitalization of $15.35 million, a price-to-earnings ratio of -0.32 and a beta of 1.88. Biocept has a 12 month low of $0.17 and a 12 month high of $1.64. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.31 and a current ratio of 2.41.
Several research analysts have recently issued reports on BIOC shares. Zacks Investment Research upgraded shares of Biocept from a “hold” rating to a “buy” rating and set a $0.25 price objective for the company in a report on Tuesday, April 17th. ValuEngine upgraded shares of Biocept from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Finally, Westpark Capital cut shares of Biocept from an “outperform” rating to a “hold” rating in a report on Wednesday, May 23rd.
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.